Novel management of urinary tract infections

Current Opinion in Urology

Volumn 21, Issue 4, 2011, Pages 328-333

  Storm, Douglas W ^a   Patel, Ashay S ^b   Koff, Stephen A ^b,c   Justice, Sheryl S ^c,d  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

interleukin 6; Mutaflor; probiotic; urinary tract infection; vesicoureteral reflux

Indexed keywords

BIOLOGICAL MARKER; MUTAFLOR; PROBIOTIC AGENT;

ARTICLE; BACTERIAL VIRULENCE; DIARRHEA; DISEASE SEVERITY; ENTERITIS; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; HOST PATHOGEN INTERACTION; HUMAN; KIDNEY INJURY; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; URINARY TRACT INFECTION; VESICOURETERAL REFLUX;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; INFANT; KIDNEY DISEASES; MALE; PROBIOTICS; RECURRENCE; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; VESICO-URETERAL REFLUX;

EID: 79959188706     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328346d4ee     Document Type: Article

References (26)

1. Craig JC, Irwig LM, Knight JF, et al. Does treatment of vesicoureteric reflux in childhood prevent end-stage renal disease attributable to reflux nephropathy? Pediatrics 2000; 105:1236-1241 (Pubitemid 30346892)
2. Conway PH, Cnaan A, Zaoutis T, et al. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA 2007; 298:179-186 (Pubitemid 47057764)
3. Garin EH, Olavarria F, Garcia Nieto V, et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006; 117:626-632 (Pubitemid 46063202)
4. Holmdahl G, Brandstrom P, Lackgren G, et al. The Swedish reflux trial in children. II: Vesicoureteral reflux outcome. J Urol 2010; 184:280-285
5. Brandstrom P, Esbjorner E, Herthelius M, et al. The Swedish reflux trial in children. III: Urinary tract infection pattern. J Urol 2010; 184:286-291
6. Brandstrom P, Neveus T, Sixt R, et al. The Swedish reflux trial in children. IV: Renal damage. J Urol 2010; 184:292-297
7. Sillen U, Brandstrom P, Jodal U, et al. The Swedish reflux trial in children. V: Bladder dysfunction. J Urol 2010; 184:298-304
8. Peters CA, Skoog SJ, Arant BS Jr, et al. Summary of the AUA guideline on management of primary vesicoureteral reflux in children. J Urol 2010; 184:1134-1144
9. Cheng CH, Tsau YK, Kuo CY, et al. Comparison of extended virulence genotypes for bacteria isolated from pediatric patients with urosepsis, acute pyelonephritis, and acute lobar nephronia. Pediatr Infect Dis J 2010; 29:736-740
10. Chiou YY, Chen MJ, Chiu NT, et al. Bacterial virulence factors are associated with occurrence of acute pyelonephritis but not renal scarring. J Urol 2010; 184:2098-2102
11. Sheu JN, Chen MC, Lue KH, et al. Serum and urine levels of interleukin-6 and interleukin-8 in children with acute pyelonephritis. Cytokine 2006; 36:276-282
12. Benson M, Jodal U, Agace W, et al. Interleukin (IL)-6 and IL-8 in children with febrile urinary tract infection and asymptomatic bacteriuria. J Infect Dis 1996; 174:1080-1084 (Pubitemid 26357473)
13. Hunstad DA, Justice SS. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol 2010; 64:203-221
14. Hunstad DA, Justice SS, Hung CS, et al. Suppression of bladder epithelial cytokine responses by uropathogenic Escherichia coli. Infect Immun 2005; 73:3999-4006 (Pubitemid 40923139)
15. Storm D, Horvath D, Li B, et al. (2010). The use of bacterial isolate cytokine analysis to assess the risk of pyelonephritis in children. In: Abstracts of the Section on Urology Annual Meeting; 2-4 October 2010; San Francisco, CA. Elk Groove Village, IL: American Academy of Pediatrics. p. 88; abstract 47
16. Storm D, Koff S, Horvath D, et al. An in vitro analysis of Escherichia Coli Nissle 1917: a new therapy to treat recurrent pediatric urinary tract infections. J Urol (in press).
17. Bharucha AE, Wald AM. Rome foundation diagnostic algorithms: anorectal disorders. Am J Gastroenterol 2010; 105:786-794
18. Kaye D. Host defense mechanisms in the urinary tract. Urol Clin North Am 1975; 2:407-422
19. Roberts JA. Etiology and pathophysiology of pyelonephritis. Am J Kidney Dis 1991; 17:1-9
20. Pennesi M, Travan L, Peratoner L, et al. Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. Pediatrics 2008; 121:e1489-e1494
21. Montini G, Rigon L, Zucchetta P, et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. Pediatrics 2008; 122:1064-1071
22. Henker J, Laass MW, Blokhin BM, et al. Probiotic Escherichia coli Nissle versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 2008; 27:494-499
23. Henker J, Laass M, Blokhin BM, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007; 166:311-318 (Pubitemid 46295098)
24. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11:853-858
25. Altenhoefer A, Oswald S, Sonnenborn U, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 2004; 40:223-229
26. Lodinova-Zadnikova R, Sonnenborn U. Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate 1997; 71:224-232 (Pubitemid 27153776)